Jim. Thanks,
excited believe we're quality are have as are and next a a to underscore our in expectations We we calendar September. results we view provide becoming take we delivering right since excited the on strategy publicly is we on and Operationally, traded that and company, company the our in in year to of first XXXX. what a are share complete the As we our that ready, results for journey from the and that IPO independent phase fully Lily. to to executing store
remaining as could in half As exchange earlier their the ownership Lily early an to first stated they begin days. Elanco the as coming today, which year, this offer intend through divest in of
and on messages Let's on start X. focus performance, and now XXXX by highlighting Slide I'd they year the are key like to for our
First, and our point XX%, grew financial basis margin our we selling revenue and was income adjusted coming less expense as is margin, are administrative. in income the all business, percentage and Productivity improvement earnings on EBIT tax, core general in In operating net adjusted XXX XXXX, improvement our before growth X%, goals. interest and year. in from a that's X facets sales delivering our manufacturing, XX%. EBIT increasing our This margin a and of sales. interest is resulted of tax and Adjusted
share year-on-year. operating improved range. us guidance for performance deliver declined our our Our of above This earnings adjusted gross year, and margin to enabled the per expenses $X.XX
and approvals: a the benefits sustainable and over three row $X.XX second XXXX was using that Prevacent, new $X.XX our should EPS with flow approach deliver time. an A in to deliver operational highlight is we tax Experior. in the range. fourth addition, year innovation was we that above a Our EPS achieved Correlink continue product drove onetime
continued of XXXX. XXXX product launching launched years over total represents doubled products the it past compared sales. animal are heartworm portfolio in Finally, well. to achieving for X% than Remember, new peak takes reached excited so a other Sales nearly for potential in sales we're blockbuster mark. oral X a the this to product year years for and sales, X million of X portfolio more reach Interceptor worms, in of products from in $XXX products. to status, fourth in on health our group the typically XXXX, now This Plus, I'll our the note,
to for example an products, we cats expand Credelio We in and also continue Europe launched XXXX. this indications is, our of in for
it's and pillars we highlights tracking and X strategy X focused, that our delivering, strategy value-generating productivity to targeted delivering the products, think Elanco flow very our mode. we're where on sustained believe agenda. executing strongly I a of we're Elanco much in our we've before, is Slide goals. and we're growth our execution of summary, discussed is in the driving of on marketed portfolio innovation,
of QX are Here key a portfolio. few starting with the the highlights
continued revenue, core increase decline and revenue, $XXX million Our our Exit And X% in core an Strategic revenue exchange of more growing top $XXX without million, portfolio impact our drove constant X% performance, exits, excluding is revenue indicative of of sales, foreign exchange. in line of again, overall or a for the rates. with these accounting X% at
and categories, our Companion Animal & are leading which again Disease Protein Future growth Prevention, now XX% Health therapeutics represent and targeted our of companimal Our animal sales growth.
launch strategy, to to since track continuing QX million of to the portfolio our our grew $XX.X of XXXX innovation XXXX revenue, in XX% over move we innovation to As our side expectations.
receiving growth during a We'll for for QX and producers grew executing have product in approval committed and on This XXXX, value the this the first-in-class million therapy in Experior, Imvixa the which we contributed of of And finally, is be in the to to necessary September. Chile, in XXXX, products Norway. In with the We XXXX after this Slide of XX% see approval met our product in approval lice for XXXX. this Imvixa. cats was received trajectory in almost third X. for are can in You cats. a work We forward $XXX Credelio sea for to Europe portfolio a novel show industry. submission authority sales these sales. salmon bringing will regulatory launched I in note, path oral our on which Norway aligned treatment almost salmon in to
our to Turning strategic third pillar, productivity.
continue additional with as the we operations. exit in we Colombia delayer and a of models, the as will technology In after physical This our activities announced and XX discussed, are In other organization also remaining you that the we sale completed. progress will expect go-to-market restructuring December, we replace costs streamline rationalization. efforts XX- the presence our Cali, QX. a with planned in site. site throughout countries our typically international of completes December, completed at tail Our footprint transfer And can to XX-month internal
X the or manufacturing of we we in and by year full we for reduced we our finishing of keeping X%; track low XX; SKUs. rationalized productivity, margin, So XX, by low to manufacturing the expenses organizations on with another volume, goal operating sites; XX% XXXX year XXX and reduced contract units, CMOs exited stock
trends thus quarterly In business variability horizon year-to-date. the business. sales to over the product our the and and at a agenda QX highlighted progress our financial I is health our the the expectations Slide productivity delivering seasonality call, for importance summarized summarizes longer currency and to of overall earlier. gauge and overall our our results of the to constant looking growth we for Our continues the to quarter categories X, Transitioning this of
highlight are our full me detail the expectations. can moment, our quarter let there you across a but will is considerations this results overall in and see more Our to main categories. QX, for to year in X point. Todd tracking that But variability X provide main
particularly a in XXXX the filings, category. Animal as First, our Disease comparison Companion $XX of reduction provides QX we favorable was Companion Prevention inventory a noted in in million. year-on-year channel Animal there IPO This approximately for of
the increased therapy, the as end XXXX. Second end projections Galliprant sales XXXX production. the backorders grow, to Galliprant in continues at are the at We of expand demand diligently companimal our discussed capacity supply we guidance call, we've of working for to exceeding And had Galliprant our of and year. for the in
of clear then impacted by antibiotics, in We of them softness growth our stock Companion expect thirdly, late These backorders cattle Swine, Asia Ruminants was And in a Therapeutics. outage swine in QX. Animal in additives particularly Micotil. early offset to or feed and & the QX growth a by
very for XXXX. growth in on our we're trends for a and are core benefit underlying highlight results X% innovator. the track -- solid, also revenue categories to These the portfolio importantly, our approach Importantly projected as our X% of
discuss to financial our Now our XXXX. I'll and call guidance over in turn more to for the detail results QX Todd review
